Momenta Pharmaceuticals Director Sells $44,664 in Stock (MNTA)
Momenta Pharmaceuticals (NASDAQ:MNTA) Director Bennett M. Shapiro sold 3,722 shares of the stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $12.00, for a total value of $44,664.00. Following the transaction, the director now directly owns 9,557 shares in the company, valued at approximately $114,684. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.
A number of research firms have recently commented on MNTA. Analysts at Maxim Group initiated coverage on shares of Momenta Pharmaceuticals in a research note on Thursday, June 5th. They set a “buy” rating and a $17.00 price target on the stock. Analysts at Goldman Sachs initiated coverage on shares of Momenta Pharmaceuticals in a research note on Monday, June 2nd. They set a “buy” rating and a $19.00 price target on the stock. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $19.20.
Momenta Pharmaceuticals (NASDAQ:MNTA) traded up 0.47% on Monday, hitting $11.785. 262,437 shares of the company’s stock traded hands. Momenta Pharmaceuticals has a 1-year low of $9.85 and a 1-year high of $19.90. The stock’s 50-day moving average is $11.32 and its 200-day moving average is $13.02. The company’s market cap is $606.7 million.
Momenta Pharmaceuticals (NASDAQ:MNTA) last released its earnings data on Thursday, July 31st. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by $0.05. The company had revenue of $11.00 million for the quarter, compared to the consensus estimate of $11.22 million. During the same quarter in the previous year, the company posted ($0.57) earnings per share. The company’s revenue for the quarter was up 151.1% on a year-over-year basis. Analysts expect that Momenta Pharmaceuticals will post $-1.14 EPS for the current fiscal year.
Momenta Pharmaceuticals, Inc (NASDAQ:MNTA) is a biotechnology company specializing in the characterization and process engineering of complex molecules.
Receive News & Ratings for Momenta Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.